Filtered By:
Condition: Hypertension
Management: WHO
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 152 results found since Jan 2013.
Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
Med Sci Monit. 2022 May 1;28:e937048. doi: 10.12659/MSM.937048.ABSTRACTThe consequences of SARS-CoV-2 infection include short-term, long-term, mild, and severe clinical symptoms. The cardiovascular system, including endothelial cells, vascular smooth muscle cells, and cardiac myocytes, are important targets for SARS-CoV-2. In February 2022, the findings from a large US cohort of individuals diagnosed with COVID-19 and two sets of control cohorts evaluated the risk and 12-month cardiovascular disease burden. Individuals who had COVID-19 had a 72% increased risk of heart failure, a 63% increased risk of myocardial infarction...
Source: Medical Science Monitor - May 1, 2022 Category: Research Authors: Dinah V Parums Source Type: research
Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research
The final puff: Can New Zealand quit smoking for good?
Smoking kills. Ayesha Verrall has seen it up close. As a young resident physician in New Zealand’s public hospitals in the 2000s, Verrall watched smokers come into the emergency ward every night, struggling to breathe with their damaged lungs. Later, as an infectious disease specialist, she saw how smoking exacerbated illness in individuals diagnosed with tuberculosis and HIV/AIDS. She would tell them: “The best thing you can do to promote your health, other than take the pills, is to quit smoking.”
Verrall is still urging citizens to give up cigarettes—no longer just one by one, but by the thousands. As New...
Source: ScienceNOW - December 9, 2022 Category: Science Source Type: news
New Urban Health ‘Accelerator’ Aims to Transform Cardiovascular Population Health Globally
May 22, 2023
GenevaThe CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.Results of initial programs in São Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% of heart attacks during implementation.Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world’s leading cause of death,according to the World Health Organizati...
Source: IntraHealth International - May 22, 2023 Category: International Medicine & Public Health Authors: cbales Tags: Global Noncommunicable Diseases Source Type: news
Ventricular global function index is associated with clinical outcomes in pediatric pulmonary hypertension
CONCLUSIONS: RV GFI was associated with CAO in this cohort, and inclusion in multivariable models had increased predictive value compared to RVEF. GFI uses readily available CMR data without additional post-processing and may provide additional prognostic value in pediatric PH patients beyond traditional CMR markers.PMID:37400886 | PMC:PMC10316558 | DOI:10.1186/s12968-023-00947-8
Source: Atherosclerosis - July 3, 2023 Category: Cardiology Authors: Hieu T Ta Paul J Critser Michal Sch äfer Nicholas J Ollberding Michael D Taylor Michael V Di Maria Russel Hirsch D Dunbar Ivy Benjamin S Frank Source Type: research
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
Partnership combines Roche ’s proven track record of successfully developing and launching innovative medicines worldwide withAlnylam ’s leadership in RNAi therapeuticsZilebesiran, a Phase 2 RNAi therapeutic, has best-in-disease potential for patients with hypertension at high risk of cardiovascular morbidity and mortality, by robustly and durably lowering blood pressureHypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need, especially for high risk patients, remains.1Basel, 24 July 2023 - Roche (SIX: RO, ROG; OT...
Source: Roche Media News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Use of hospital services by patients with chronic conditions in sub-Saharan Africa: a systematic review and meta-analysis
CONCLUSION: Among patients seeking hospital care in sub-Saharan Africa, multimorbidity remains poorly described despite high burdens of individual chronic diseases. Prospective public health studies of multimorbidity burden are needed to generate integrated and context-specific health system interventions that act to maximize patient survival and well-being.PMID:37638357 | PMC:PMC10452942 | DOI:10.2471/BLT.22.289597
Source: Bulletin of the World Health Organization - August 28, 2023 Category: International Medicine & Public Health Authors: Stephen A Spencer Jamie Rylance Jennifer K Quint Stephen B Gordon Paul Dark Ben Morton Source Type: research
Effects of sotatercept on haemodynamics and right heart function: analysis of STELLAR trial
CONCLUSION: In pre-treated patients with PAH, sotatercept demonstrated substantial improvements in PA pressures, PA compliance, PA-RV coupling and right heart function.PMID:37696565 | DOI:10.1183/13993003.01107-2023
Source: Respiratory Care - September 11, 2023 Category: Respiratory Medicine Authors: Rogerio Souza David B Badesch H Ardeschir Ghofrani J Simon R Gibbs Mardi Gomberg-Maitland Vallerie V McLaughlin Ioana R Preston Aaron B Waxman Ekkehard Gr ünig Grzegorz Kope ć Gisela Meyer Karen M Olsson Stephan Rosenkranz Jianxin Lin Amy O Johnson-Levo Source Type: research
